ArticleObstetrics and gynecology2018
Moving Toward Individualized Medicine for Uterine Leiomyomas.
Article in Obstetrics and gynecology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- The efficacy and safety of Chinese herbal medicine Shugan Sanjie decoction in the treatment of uterine fibroids: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- The efficacy and safety of Chinese herbal medicine Guizhi Fuling capsule combined with low dose mifepristone in the treatment of uterine fibroids: a systematic review and meta-analysis of 28 randomized controlled trials.BMC complementary medicine and therapies · 2023Pooled it
- Effectiveness of a hysteroscopic tissue removal system device for hysteroscopic myomectomy on patients' quality of life: a randomized clinical trial.BMC women's health · 2023Trial
- Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.The New England journal of medicine · 2021Trial
- Adenomyosis and Uterine Fibroids: Two Distinct Yet Overlapping Clinical Entities.Diagnostics (Basel, Switzerland) · 2026Review
- Health-Related Quality of Life in Women with Uterine Fibroids Recruited from Clinical and Online Settings: A Cross-Sectional Comparative Study.Journal of clinical medicine · 2026Article
- Massive Uterine Leiomyomatosis Requiring Hysterectomy in a 25-Year-Old Woman: A Case Report.Cureus · 2026Article
- Health-Related Quality of Life, Anxiety, and Stress in Women with Uterine Fibroids: A Cross-Sectional Analysis.Journal of clinical medicine · 2026Article
- An Unexpected Intraoperative Discovery: A Parasitic Leiomyoma in a Perimenopausal Patient With Complex Abnormal Uterine Bleeding.Journal of medical cases · 2026Article
- Physician Management of Non-Cavity Distorting Intramural Fibroids and Infertility: A Survey of REI Providers.International journal of women's health · 2026Article
- Article
- Detection of exon2-MED12 mutations in uterine leiomyomas from Syrian patients.Scientific reports · 2025Article
- Increased Occurrence of Cutaneous Leiomyomas and Dermatofibromas in Patients with Uterine Leiomyomas without Fumarate Hydratase Gene Mutations.Dermatopathology (Basel, Switzerland) · 2023Article
- Characteristics of Submucous Myomas and the Risk of Anemia.Medicina (Kaunas, Lithuania) · 2022Article
- Review
- Uterine Fibroids: Hiding in Plain Sight.Physiology (Bethesda, Md.) · 2022Review
- Value of Strain-Ratio Elastography in the Diagnosis and Differentiation of Uterine Fibroids and Adenomyosis.Journal of personalized medicine · 2021Article
- Haplotypes of CYP1B1 and CCDC57 genes in an Afro-Caribbean female population with uterine leiomyoma.Molecular biology reports · 2019Article
- Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas.JCO precision oncology · 2019Article
- Transvaginal Ultrasound and Laparoscopy-guided Microwave Ablation for Uterine Myoma and Adenomyosis: Preliminary Results.Gynecology and minimally invasive therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Uterine leiomyomas are common and life-altering for many women. Despite a wide range of symptoms, varying characteristics of the uterus and the leiomyomas themselves, and many alternatives, hysterectomy accounts for almost three fourths of all surgical therapy, yet there is increasing evidence for a variety of procedural therapies for symptomatic leiomyomas and a new generation of medical therapies under development. With increasing evidence of long-term risk from hysterectomy and new data regarding leiomyoma biology, individualized medical approaches to leiomyomas are likely in the near future. Key biological attributes that influence this disease process are common driver mutations and the new appreciation of the interaction of smooth muscle cells and fibroblasts. Additionally, the interaction between cell types and steroid hormone responsiveness likely plays a role in pathogenesis that can be leveraged in individualized therapy. However, given the independent clonal nature of leiomyomas within the same uterus, moving in the direction of biopsies for individual leiomyomas to understand the biology is unlikely to be fruitful. Use of advanced imaging will likely continue to evolve not only to accurately predict malignant disease, including sarcomas, but to predict leiomyoma subtypes, response to therapy, or both. We predict the continued evolution of therapy from excisional or interventional therapies to medical therapies and ultimately prediction of at-risk individuals. Ideally, individualized therapies will offer primary prevention for women at high risk of leiomyomas and secondary prevention after initial treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.